RE:Trial NRThose were actually 2 good news releases not one.
I would have liked to see the actual numbers from the study, but saying that the primary end-point was met, and that the secondary endpoint was positive is excellent news imo.
The long half-life, meaning once-a-week dosing, as opposed to once-a-day what you have on the market currently, is also fantastics.
My take on the selling is that there is quite a bit of investor fatigue with the story as it has been around for a while now. This happens to every stock, so understandeable. Personally I didn't expect it here, in what I consider to be a long stretch, but I've seen the same thing with Bioasis...there was a huge overhang at $0.60 before the stock took off.
Now we need some promotion to expand the shareholder base, to get the people talking and speculating on this fantastic opportunity. Afterall we are talking about potentially a great new drug in a multi $b Type II diabetes market!
Expecting a great end of year run with lots of speculation and excitement with the chronic phase II study. Good luck all.
Cheers,
TB